Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
about
Gene-wide characterization of common quantitative trait loci for ABCB1 mRNA expression in normal liver tissues in the Chinese populationEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyNo influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patientsAntiretroviral therapy and dyslipidaemia: unlocking the code.Pharmacogenetics as a tool to tailor antiretroviral therapy: A reviewPharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsIndividualization of antiretroviral therapy--pharmacogenomic aspectPlasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsFunctional impact of ABCB1 variants on interactions between P-glycoprotein and methadoneCYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiNucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region.Association of ABCB1 genetic variants with renal function in Africans and in Caucasians.A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.Characteristics of compounds that cross the blood-brain barrierGenetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsAntagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors.Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.Drug resistance in brain diseases and the role of drug efflux transporters.Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?Relationship between P-glycoprotein and second-generation antipsychotics.Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohortPopulation pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitisPerceptions of genetic testing and genomic medicine among drug users.Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.Advances in the development of genetic markers for the diagnosis of disease and drug response.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy.Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success
P2860
Q21560761-E994B20D-30AB-430F-B011-9F5342E77519Q24633579-67533BEA-6F71-4D1F-AF97-B48D62937746Q24803662-CFE94080-EAAB-41F5-9C79-BF01E3154F63Q25256933-741F5608-8F39-41AC-8F7C-6F40A4C98FF2Q26797938-6C851A14-4245-4C1C-95F7-C93DD9463DCAQ28069383-70EEF9FA-C1D7-4960-8BC5-DE9D69178563Q28070574-988D9962-B247-48DE-9EFB-040B0F5C96CEQ28286926-57ED6874-EB1A-427C-A586-5860FD4429B2Q28293875-1C0C1DD5-3A40-4E10-A694-F3470496FE26Q28488223-25A45504-A421-4FEA-89E1-814B989056A6Q30438405-0EF73FAF-52B7-494A-ADDB-C8D971EFFD0CQ33242896-D1A89D53-9F7D-4B69-9BC1-C6BF32FAEC62Q33339723-D6FE1DDC-679D-40C5-A1CF-0C9DB2720AACQ33447663-9D5D039A-EF12-4A47-8C58-BB3BD779EF3DQ33469828-AEAC6A1A-9FD7-4EA3-A27C-9FE6BFCB3BA6Q33632608-9FFF08BE-D51C-4671-AC24-7AC11F929781Q33807628-E3B212BA-3DE3-4005-A764-8B68B34CB9E9Q33864976-74A4FA2E-D843-4A29-A4AA-719B3444A6C3Q33933907-AB3D98FB-A783-49FE-80E6-5E4E7F7CDECAQ33954823-A4F67603-EEC6-4225-B240-7BA4CCBB81F3Q33988704-58D776BC-2C5E-40F0-AABC-CA350E2AC6D6Q34129436-60F433C2-D681-4C41-A31F-B319F3B46F87Q34151189-DED2E457-C13A-4A6F-8630-36704E7C7038Q34190195-14B7D023-3215-496F-9022-384C6A4FEF1FQ34208133-A1FC71D5-6C6B-40E7-8A42-0F775A72333FQ34327594-4D0469BD-C8B7-47AF-A5E0-CD1E6EA6BDA4Q34443184-66518A2A-F4A2-467B-9AD8-488630752808Q34538009-679F5981-5AF1-4188-A210-E2A9A6EA5CE5Q34571645-58EDC372-F3C7-4C1E-8991-929E6F66FC19Q34721793-E5E7F74B-B37D-4A7C-AE5A-7075A2D65300Q34754376-C9AA9FBB-9185-4312-B44E-BB07A5FB1FE4Q34756398-1A41E9A5-9E20-405E-A4E3-A0F3B3F67FB8Q34761828-DF5BAA97-D15A-4A99-AD0A-34038271C653Q34772602-8B223CF4-12B0-4F3D-BF9F-27D80475B491Q34775319-C1B81F3C-B86D-47F5-BA24-361527EBDE8EQ34884611-BDD3D42E-C267-4C89-9EBC-9A6E758C3664Q35000765-1D6B3866-EF8D-4FB4-9ABC-1882AE4FA755Q35000912-39389131-EC69-4BEF-94F7-3D285E19544BQ35018246-130596A3-C890-4A97-A66D-B48EE686C234Q35043700-71011DD7-41BF-4C74-AB4E-7D40DDEE2922
P2860
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@en
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@nl
type
label
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@en
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@nl
prefLabel
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@en
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@nl
P2093
P50
P1433
P1476
Response to antiretroviral tre ...... r 1: a pharmacogenetics study.
@en
P2093
Alfred H Schinkel
Amalio Telenti
Catia Marzolini
David J Back
Dorota Retelska
Emma R Meaden
Giuseppe Pantaleo
Jean Philippe Chave
Laurent A Decosterd
Lidia Ruiz
P356
10.1016/S0140-6736(02)07276-8
P407
P577
2002-01-01T00:00:00Z